Investors often fear bear markets. But as much as we enjoy bull markets, we also need to embrace the bumpy periods too as part and parcel of how the markets work. We can learn to appreciate these periods by having a solidly diversified portfolio of stocks that work for us in different investing environments -- and by using bear markets to identify companies with strong, long-term opportunities that should soar when the bull comes back. Read More...
SmarterAnalyst
Atea Reveals Topline Results of Phase 2 MOONSONG Trial; Shares Crash 66%
Shares of Atea Pharmaceuticals (AVIR) plunged 66% on Tuesday to close at $13.82 after the clinical-stage biopharmaceutical company provided update and topline results of the Phase 2 MOONSONG trial. Notably, the trial was evaluating AT-527 in the outpatient setting. The global Phase 2 MOONSONG trial, a randomized, double-blind, multi-center, placebo-controlled trial, was evaluating the antiviral activity, safety and pharmacokinetics of AT-527 550 mg and 1,100 mg, which was administered twice dail
Add Comment